Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: A prospective observational study

American Journal of Cardiovascular Drugs

Volumn 13, Issue 1, 2013, Pages 27-35

  Bytzer, Peter ^a   Pratt, Stephen ^b   Elkin, Eric ^c   Næsdal, Jørgen ^d   Sörstadius, Elisabeth ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Harmony Clinical Research   (United States)

^c ICON CLINICAL RESEARCH   (United States)

^d ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR RISK; DYSPEPSIA; EMOTION; FEMALE; FRANCE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; HEALTH CARE UTILIZATION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGICAL WELL BEING; RECOMMENDED DRUG DOSE; RISK MANAGEMENT; SLEEP QUALITY; STRESS; TREATMENT DURATION; UNITED STATES; UPPER GASTROINTESTINAL TRACT;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK MANAGEMENT; SLEEP; UPPER GASTROINTESTINAL TRACT; YOUNG ADULT;

EID: 84874088011     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-012-0001-4     Document Type: Article

References (42)

1. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849- 60.
2. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004;25(2):166-81.
3. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J. 2006;27(22):2667-74.
4. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis. J Intern Med. 2005;257(5):399-414.
5. Maulaz AB, Bezerra DC, Michel P, et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol. 2005;62(8):1217-20.
6. Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis. 2010;103(6-7):363-75.
7. Collet JP, Montalescot G, Blanchet B, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110(16):2361-7.
8. Ferrari E, Benhamou M, Cerboni P, et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45(3):456-9.
9. Eisenberg MJ, Richard PR, Libersan D, et al. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009;119(12):1634-42.
10. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163-73.
11. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology. 2001;120(3):594-606.
12. Serrano P, Lanas A, Arroyo MT, et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16(11):1945-53.
13. Taha AS, Angerson WJ, Prasad R, et al. Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008;28(7):878-85.
14. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22(9):795-801.
15. Camilleri M, Dubois D, Coulie B, et al. Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study. Clin Gastroenterol Hepatol. 2005;3(6):543-52.
16. Nandurkar S, Talley NJ, Xia H, et al. Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Arch Intern Med. 1998;158(13):1427-33.
17. Heading RC. Prevalence of upper gastrointestinal symptoms in the general population: a systematic review. Scand J Gastroenterol. 1999;231(Suppl):3-8.
18. Whitaker MJ, Brun J, Carelli F. Controversy and consensus in the management of upper gastrointestinal disease in primary care. The International Gastro Primary Care Group. Int J Clin Pract. 1997;51(4):239-43.
19. Pratt S, Thompson VJ, Elkin EP, et al. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs. 2010;10(5):281-8.
20. Caprie Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996;348(9038):1329-39.
21. Bytzer P. Dyspepsia as an adverse effect of drugs. Best Pract Res Clin Gastroenterol. 2010;24(2):109-20.
22. Cayla G, Collet JP, Silvain J, et al. Prevalence and clinical impact of upper gastrointestinal symptoms in subjects treated with low dose aspirin: the UGLA survey. Int J Cardiol. 2012;156(1):69-75.
23. van Bommel MJ, Numans ME, de Wit NJ, et al. Consultations and referrals for dyspepsia in general practice - a one year database survey. Postgrad Med J. 2001;77(910):514-8.
24. Broker LE, Hurenkamp GJ, ter Riet G, et al. Upper gastrointestinal symptoms, psychosocial co-morbidity and health care seeking in general practice: population based case control study. BMC Fam Pract. 2009;10:63.
25. Krystal AD, Walsh JK, Laska E, et al. Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. Sleep. 2003;26(7):793-9.
26. Roth T, Walsh JK, Krystal A, et al. An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. Sleep Med. 2005;6(6):487-95.
27. Scharf M, Erman M, Rosenberg R, et al. A 2-week efficacy and safety study of eszopiclone in elderly patients with primary insomnia. Sleep. 2005;28(6):720-7.
28. Zammit GK, McNabb LJ, Caron J, et al. Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia. Curr Med Res Opin. 2004;20(12):1979-91.
29. Shiffman S, Paty JA, Gnys M, et al. First lapses to smoking: within-subjects analysis of real-time reports. J Consult Clin Psychol. 1996;64(2):366-79.
30. Palermo TM, Valenzuela D, Stork PP. A randomized trial of electronic versus paper pain diaries in children: impact on compliance, accuracy, and acceptability. Pain. 2004;107(3):213-9.
31. Cates C, Roberts L, Eremenco S, et al. Can older, chronically ill adults use electronic diaries? Compliance rates in a prospective study of COPD [abstract]. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Orlando; 2009.
32. Reed D, Curry C, Rocchio S, et al. COPD eDiary compliance: comparison of age, symptom score, duration in clinical trial and country of origin [abstract]. European Respiratory Society (ERS), Barcelona; 2010.
33. Stone AA, Broderick JE, Schwartz JE, et al. Intensive momentary reporting of pain with an electronic diary: reactivity, compliance, and patient satisfaction. Pain. 2003;104(1-2):343-51.
34. Herlitz J, Tóth PP, Næsdal J. Low-dose acetylsalicylic acid therapy for CV prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs. 2010;10(2):125-41.
35. Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103(10):2465-73.
36. Muller P, Simon B. The action of the proton pump inhibitor pantoprazol against acetylsalicylic acid-induced gastroduodenopathy in comparison to ranitidine. An endoscopic controlled, double blind comparison [in German]. Arzneimittelforschung. 1998;48(5):482-5.
37. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011;97(10):797-802.
38. Lanas A, Rodrigo L, Marquez JL, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol. 2003;38(7):693-700.
39. Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346(26):2033-8.
40. Laheij RJ, Van Rossum LG, Jansen JB, et al. Proton-pump inhibitor therapy for acetylsalicylic acid associated upper gastrointestinal symptoms: a randomized placebo-controlled trial. Aliment Pharmacol Ther. 2003;18(1):109-15.
41. Quittner AL, Modi AC, Lemanek KL, et al. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Pediatr Psychol. 2008;33(9):916-36.
42. Margolis MK, Halling K, Sörstadius E, et al. Upper gastrointestinal symptoms experienced by users of low-dose aspirin (acetylsalicylic acid) [75-325 mg/day] for primary and secondary coronary artery disease prevention: perspectives from patient focus groups. Patient. 2009;2(2):89-93.